Blood marker may forecast COPD danger

NCT ID NCT07154953

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether certain substances in the blood, like surfactant protein-D (SP-D), can help doctors predict how severe a COPD attack will be in hospitalized patients. Researchers will measure these markers in 75 adults admitted for a COPD flare-up and compare them to standard tests and patient outcomes. The goal is to find a reliable way to identify high-risk patients early, so they can receive more intensive care sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a simple blood test that helps doctors predict how severe a COPD flare-up will be, allowing for faster and more personalized treatment.

What could go wrong

This is a small, early-stage observational study, not a treatment trial. The markers may not prove reliable enough for routine use, and results may not apply to all COPD patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••